The Clovis Oncology Inc. (NASDAQ:CLVS) is going up by 5.43% in today’s trading session, a rise equivalent to 0.38% of the stock’s price from yesterday’s market close. A news came out on 11/13/19 stating that Clovis Oncology Announces Reimbursement for Rubraca(R) (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy by WSJ. The lowest point that the shares touched during the trading session was $6.26, while the peak of the day was recorded at a share price of $7.17. CLVS finished the previous session at $7.06 according to the data provided by Barchart, while the trading volume was observed to be $10399973.
In the 100 days of trading, CLVS managed to top a 6.66% Moving average. Additionally, Clovis Oncology Inc. shares have achieved a 52-week range between 2.93 and 32.05 alongside 100 days raw stochastic set at 43.91%.
The number of shares outstanding, according to the fundamentals of the company, is set at 54.22M, equal to the value of $382.79M in market capitalization. In the last 30 days, Clovis Oncology Inc. shares went down by -8.41%, adding 8.20 to growth in value, on top of a +156.31% boost since 10/18/19.
Clovis Oncology Inc. (NASDAQ:CLVS) Analyst’s Estimates
Clovis Oncology Inc. (CLVS) could record at least -$1.70 per share in quarterly earnings in the upcoming report on 02/25/2020, a number that would actually represent a decrease of -5.49 YOY.
According to the average analyst rating, Clovis Oncology Inc. would be rated as Hold. Out of 10 different analysts monitoring CLVS stock, 3 analysts rate the stock as a BUY, 6 suggest to give the rating of HOLD, 0 indicate that CLVS is an OVERWEIGHT, 1 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERWEIGHT.
On November 19, 2019, the stock earned a Downgrade rating due to a new analyst call from Evercore ISI, while analysts from SVB Leerink believe that the stock is set at Mkt Perform from Outperform, as concluded on September 24, 2019. BofA/Merrill, is still rather wary about the stock, deciding to keep the rating at Neutral as confirmed through a call on August 13, 2019.
Goldman, on the other hand, provided a rather enthusiastic opinion on the rating, concluded in an analyst call on May 29, 2019, giving the stock a Sell from the Neutral rating.
CLVS Key Ratios To Watch:
Beta value of the stock is recorded at 1.97. Additionally, Clovis Oncology Inc. is recording price volatility of 14.18% for the period of the last seven days and 13.88% in the last 30 days.
Clovis Oncology Inc. (NASDAQ:CLVS) Technical Outlook
For the period of the last 50 days, Clovis Oncology Inc. had its Raw Stochastic average set at 86.91% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 86.91%. Stochastic %K for Clovis Oncology Inc., with the last 20 days included, was set at 89.69%, having Stochastic %D topping 88.41%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be discouraging for Clovis Oncology Inc. stocks with recording -60.69% in metrics.
Clovis Oncology Inc. Insider Watch:
Similarly, 106.86% of the company’s float is held by institutions – and there are 247 institutions in total holding shares of this company. The top three institutional holders of CLVS stocks are: Blackrock Inc. with ownership of $19.16 million, which is approximately 4874868 of the company’s shares; Palo Alto Investors Lp, holding 4720744 shares of the stock with an approximate value of $18.55 million; and Vanguard Group, Inc. (The), currently with more than 4513843 shares of the company valued at $17.74 million. Positions in Clovis Oncology Inc. stocks held by institutional investors has been changing actively in the past six months, a period during which there were 20 insider purchases amounting to 180617 shares. Similarly, there were 14 sale transactions amounting to 10122 shares, with the net shares purchased during the last six months reaching 170,495.